Tremfya (guselkumab) is an injectable biologic medication approved to treat four inflammatory conditions: moderate-to-severe plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. It works by blocking a specific immune signal called IL-23 that drives chronic inflammation in the skin, joints, and gut.
How Tremfya Works
IL-23 is an immune protein that acts like a switch, triggering a cascade of inflammatory signals throughout the body. In people with autoimmune conditions, this switch stays stuck in the “on” position, causing the immune system to attack healthy tissue. Tremfya targets and neutralizes the unique part of the IL-23 molecule (called the p19 subunit), shutting down that cascade without broadly suppressing the immune system the way older treatments do.
By cutting off IL-23, Tremfya reduces the downstream production of dozens of inflammatory molecules responsible for the red, scaly plaques of psoriasis, the swollen joints of psoriatic arthritis, and the intestinal damage seen in inflammatory bowel disease.
Plaque Psoriasis
Plaque psoriasis was the first condition Tremfya was approved to treat, and it remains the drug’s strongest indication in terms of clinical data. In the two pivotal trials (VOYAGE 1 and VOYAGE 2), about 70 to 73% of patients achieved 90% skin clearance by week 16, compared to just 2 to 3% on placebo. For context, 90% clearance means the vast majority of plaques are gone, not just improved.
Tremfya also outperformed adalimumab (Humira) in head-to-head comparisons. At week 48, 76% of Tremfya patients maintained 90% clearance versus 48% on adalimumab. Complete clearance told a similar story: 47% of Tremfya patients had zero visible plaques at one year, compared to 23% on adalimumab.
Long-term data is particularly encouraging. After five years of continuous use in the VOYAGE 2 trial, 82% of patients still maintained 90% skin clearance, and more than half (53%) had complete clearance with no visible plaques at all. These results held up even when patients who dropped out for any reason were counted as failures.
Tremfya is approved for adults and children ages 6 and older (weighing at least 40 kg, roughly 88 pounds) with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or light therapy.
Psoriatic Arthritis
Beyond skin symptoms, Tremfya is approved for active psoriatic arthritis in adults and children 6 and older (again, at least 40 kg). Psoriatic arthritis causes joint pain, stiffness, and swelling that can lead to permanent joint damage if untreated. Because IL-23 fuels inflammation in both the skin and joints, blocking it addresses both problems simultaneously.
The dosing schedule for psoriatic arthritis is the same as for plaque psoriasis. Many patients with psoriatic arthritis also have skin plaques, so a single medication can manage both conditions.
Ulcerative Colitis
Tremfya received FDA approval for moderately to severely active ulcerative colitis in adults. This made it part of a newer wave of biologics targeting the gut inflammation that causes the bloody diarrhea, urgency, and cramping characteristic of the disease.
Treatment for ulcerative colitis follows a two-phase approach. The induction phase uses higher doses given by IV infusion at a clinic or infusion center at weeks 0, 4, and 8. After that initial period, patients transition to self-administered injections at home for ongoing maintenance, given every 4 or 8 weeks depending on the dose. This shift from IV to injection means fewer clinic visits over time.
Crohn’s Disease
Crohn’s disease is the most recently added indication. Like ulcerative colitis, Crohn’s involves chronic inflammation of the digestive tract, but it can affect any part of the GI system and often penetrates deeper into the intestinal wall. Tremfya is approved for moderately to severely active Crohn’s disease in adults.
The dosing pattern mirrors ulcerative colitis: an induction phase followed by maintenance injections. One difference is that Crohn’s patients have the option of receiving their induction doses either by IV infusion or by subcutaneous injection, giving some flexibility in how treatment begins. Pediatric use has not been established for either bowel condition.
What Treatment Looks Like
For psoriasis and psoriatic arthritis, Tremfya is given as a 100 mg injection under the skin. You get your first dose, a second dose four weeks later, and then one dose every eight weeks after that. Many patients learn to self-inject at home using a prefilled syringe or autoinjector, which means visits to a clinic are mainly needed early on.
For ulcerative colitis and Crohn’s disease, the process is more involved at the start. The three induction infusions require sitting in an infusion chair for at least an hour each time. Once you move to the maintenance phase, the convenience improves considerably since you switch to injections you can do at home.
Side Effects and Safety
Tremfya carries no boxed warnings, which is notable for a biologic medication. The most common side effect is upper respiratory infections (things like colds and sinus infections), reported in about 14% of patients in trials. Other reactions occurring in more than 1% of patients included headache (4.6%), injection site reactions (4.5%), joint pain (2.7%), diarrhea (1.6%), stomach bugs (1.3%), and fungal or herpes simplex infections (about 1% each).
Overall infection rates were only slightly higher with Tremfya than with placebo in trials: 23% versus 21%. Serious infections were rare, occurring in 0.2% or fewer patients in both groups. That said, Tremfya should not be started during an active infection, and people with chronic or recurrent infections need careful consideration before beginning treatment. Because the drug modifies immune function, staying aware of new or worsening infections is important throughout treatment.